Advancing Globalization
First written in FY2016. 25 of 33 entries say "Advanced", first in FY2017. Latest entry: 2026-08-07.
32 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「Breakdown: Overseas business revenue: ¥87,474 million (up 25.1% year on year); breakdown: overseas business operating profit: ¥16,997 million (up ¥9,521 million year on year)」
The overseas business increased both revenue and profit, supported by contributions from MILEI, the bacterial-strain business and NutriCo Morinaga. - FY2026-H1AdvancedAnnual report
「Breakdown: Overseas business revenue: ¥39,398 million (up 12.6% year on year); overseas business operating profit: ¥6,845 million (up ¥4,884 million year on year)」
The overseas business increased both revenue and profit, driven by higher revenue and profit at MILEI against a backdrop of whey market conditions, as well as steady performance by the bacterial-strain business and NutriCo Morinaga in Pakistan. - FY2025-H1Overseas business: higher revenue, lower profitAnnual report
「Overseas business: Although the overseas business was affected by a reactionary decline at MILEI GmbH (MILEI), which had expanded substantially in the first quarter of the previous fiscal year, overall revenue increased due to higher revenue at Morinaga Nutritional Foods, Inc. (MNF) in the United States and steady exports of bacterial strains. Profit declined overall due to the impact of the reactionary decline at MILEI and delays in the recovery of other subsidiaries.」
Overseas business revenue increased 1.9% year on year to ¥34,979 million, supported by higher revenue at MNF in the United States and steady exports of bacterial strains, while operating profit fell to ¥1,848 million, down ¥2,102 million from the previous fiscal year due to the reactionary decline at MILEI and other factors. - FY2024AdvancedAnnual report
「Overseas business: Although the export business and MILEI GmbH (MILEI), which also saw a reactionary decline after its substantial expansion in the previous fiscal year, both declined in revenue, the overall business increased revenue, helped by NutriCo Morinaga (Pvt.) LTD., Turtle Island Foods, Inc. and Morinaga Le May Vietnam Joint Stock Company, which became newly consolidated subsidiaries through M&A.」
The newly consolidated subsidiaries acquired through M&A in Pakistan, the United States and Vietnam contributed to higher overseas business revenue. Overseas business revenue reached ¥60,422 million, while operating profit declined due to the reactionary decline at MILEI, amortisation of goodwill and other factors. - FY2024-Q3AdvancedAnnual report
「Overseas business: Although the export business and MILEI GmbH (MILEI), which also saw a reactionary decline after its substantial expansion in the previous fiscal year, both declined in revenue, the overall business increased revenue, helped by NutriCo Morinaga (Pvt.) LTD. (NutriCo Morinaga), Turtle Island Foods, Inc. (Turtle Island Foods) and Morinaga Le May Vietnam Joint Stock Company (Morinaga Le May), which became newly consolidated subsidiaries through M&A.」
The newly consolidated subsidiaries acquired through M&A in Pakistan, the United States and Vietnam contributed, and overseas business revenue reached ¥48,359 million, up 6.6% year on year despite a reactionary decline at MILEI. Operating profit, however, was ¥4,899 million, down ¥1,765 million from the previous fiscal year. - FY2024-Q2AdvancedAnnual report
「Overseas business: Although the export business declined in revenue, the overall business increased revenue, helped by MILEI GmbH (MILEI), which manufactures and sells dairy ingredients, and by NutriCo Morinaga (Pvt.) LTD. (NutriCo Morinaga), Turtle Island Foods Holdings, Inc. (Turtle Island Foods) and Morinaga Le May Vietnam Joint Stock Company (Morinaga Le May), which became newly consolidated subsidiaries through M&A.」
In addition to MILEI, the companies newly consolidated through M&A in Pakistan, the United States and Vietnam contributed to the overseas business, whose revenue was ¥34,324 million, up 16.8% year on year. - FY2024-Q1AdvancedAnnual report
「In the overseas business, in addition to the core MILEI GmbH (MILEI) business, we are steadily putting on track the business plans arising from the M&A transactions carried out in Pakistan, the United States and Vietnam in the previous fiscal year, while pursuing further initiatives aimed at medium- to long-term growth.」
The company is advancing the business plans for the M&A transactions carried out in Pakistan, the United States and Vietnam. Overseas business revenue was ¥17,629 million, up 29.5% year on year, and operating profit was ¥2,781 million. - FY2023-Q3AdvancedAnnual report
「The shares of the target company were acquired as of 18 January 2023, making it a subsidiary.」
NutriCo Morinaga became a subsidiary as of 18 January 2023, and its voting rights ratio was raised from 17.73% to 51.00%. The expansion of the overseas business through the infant-formula business in Pakistan is proceeding in concrete terms. - FY2023-Q2AdvancedAnnual report
「Expansion of the overseas business, including expansion of existing businesses and the execution of a share transfer agreement for NutriCo Morinaga (Private) Limited」
The company advanced the expansion of its overseas business, including the execution of a share transfer agreement for NutriCo Morinaga. Overseas business revenue was ¥29,389 million, up 40.4% year on year. - FY2023-Q1AdvancedAnnual report
「At a meeting of the Board of Directors held on 14 July 2022, the company resolved to enter into a basic agreement to acquire additional shares in its affiliate NutriCo Morinaga (Private) Limited (NutriCo Morinaga), with the aim of making it a consolidated subsidiary.」
Regarding NutriCo Morinaga, which operates an infant-formula business in Pakistan, the company resolved to enter into a basic agreement to increase its voting rights ownership from 17.73% to 51.00% following the additional acquisition. The stated share purchase price is US$57,003,000 (approximately ¥7,695 million, including advisory fees), while the execution of the share transfer agreement and the acquisition of subsidiary status have not yet been determined. - FY2022AdvancedAnnual report
「Overseas business revenue: ¥43,862 million (up 19.2% year on year)」
Overseas business revenue increased 19.2% year on year, driven by higher revenue at MILEI, the consolidation of Elovi as a subsidiary and the expansion of functional ingredients. - FY2022-Q3AdvancedAnnual report
「Overseas business revenue ¥32,533 million (up 11.8% year on year)」
For the overseas business, including MILEI, Elovi in Vietnam and functional ingredients, cumulative nine-month revenue was ¥32,533 million, up 11.8% year on year. Operating profit also reached ¥5,692 million, reflecting profit growth driven by the expansion of functional ingredients and other factors. - FY2022-Q2AdvancedAnnual report
「④ Overseas business: Exports of infant formula and other products declined in revenue following the substantial increase in the previous fiscal year, but MILEI, which manufactures and sells dairy ingredients, reported higher revenue. Revenue also increased due in part to the addition of Elovi in Vietnam as a consolidated subsidiary in March 2021.」
Overseas business revenue increased, driven by higher revenue at MILEI and the contribution of Elovi in Vietnam, which became a consolidated subsidiary in March 2021. Overseas business revenue was ¥20,939 million, up 9.8% year on year, while operating profit was ¥3,647 million, an increase of ¥918 million from the previous fiscal year. - FY2022-Q1AdvancedAnnual report
「Voting rights ratio acquired on the date control was obtained: 51.00%; additional voting rights ratio acquired after control was obtained: 48.98%; voting rights ratio after the additional acquisition: 99.98%」
Additional shares in Elovi were acquired on 22 June 2021, raising the voting rights ratio from 51.00% to 99.98%. - FY2021AdvancedAnnual report
「January 2021: Acquired 51% of the shares of Elovi Vietnam Joint Stock Company (Vietnam), now a consolidated subsidiary.」
In January 2021, 51% of the shares of Elovi in Vietnam were acquired, and it became a consolidated subsidiary from March 2021. Overseas business revenue was ¥37,249 million, up 18.2% year on year. - FY2021-Q3AdvancedAnnual report
「④ Overseas business: MILEI, which manufactures and sells dairy ingredients, reported higher revenue due to increased demand for milk powder and other products. Exports of infant formula and other products also rose sharply from the previous fiscal year, reflecting a rebound. In addition, sales of functional ingredients, including bacterial strains and lactoferrin, increased.」
Overseas business revenue increased 23.8% year on year to ¥29,461 million, driven by higher revenue at MILEI, increased exports of infant formula and other products, and higher sales of functional ingredients. - FY2021-Q2AdvancedAnnual report
「④ Overseas business: MILEI, which manufactures and sells dairy ingredients, reported higher revenue due to increased demand for milk powder and other products. Exports of infant formula and other products also rose sharply from the previous fiscal year, reflecting a rebound. In addition, sales of functional ingredients, including bacterial strains and lactoferrin, increased. Overseas business revenue: ¥19,297 million (up 23.5% year on year)」
Overseas business revenue increased 23.5% year on year to ¥19,297 million, driven by higher revenue at MILEI, increased exports of infant formula and other products, and higher sales of functional ingredients. - FY2021-Q1AdvancedAnnual report
「Overseas business revenue: ¥9,801 million (up 24.9% year on year)」
Overseas business revenue increased 24.9% year on year, driven by higher revenue at MILEI, increased exports of infant formula and other products, and higher sales of functional ingredients. - FY2020AdvancedAnnual report
「Pakistan business: The local factory in Pakistan began operations, manufacturing and newly launching 3 types of infant formula (8 SKUs).」
The local factory in Pakistan began operations, and the company reached the stage of manufacturing and launching infant formula. It also describes product development for Indonesia, Myanmar and the Philippines. - FY2020-Q3RestatedAnnual report
「We are also pursuing proactive sales promotion for functional ingredients that contribute to health, as well as expanding our overseas business.」
The overseas business continues as a measure alongside sales promotion for functional ingredients. - FY2020-Q2RestatedAnnual report
「We are also pursuing proactive sales promotion for functional ingredients that contribute to health, as well as expanding our overseas business.」
The overseas business continues to expand alongside sales promotion for functional ingredients. - FY2020-Q1RestatedAnnual report
「We are also pursuing proactive sales promotion for functional ingredients that contribute to health, as well as expanding our overseas business.」
The overseas business continues to expand alongside sales promotion for functional ingredients. - FY2019AdvancedAnnual report
「The safety of Shield Lactic Acid Bacteria® was assessed under the U.S. regulatory system, making sales in the United States possible.」
As part of the expansion of the overseas business, the area where Shield Lactic Acid Bacteria can be sold has been concretely expanded through U.S. regulatory clearance. - FY2018RestatedAnnual report
「Measures to strengthen the business, including investment in domestic yogurt production facilities, establishing a joint venture in Pakistan for the manufacture and sale of infant formula, and developing the yogurt business in the United States, have been decided on and initiated.」
It reiterates domestic capital investment, the Pakistan joint venture and the U.S. yogurt business as initiatives that were decided on and launched. - FY2017AdvancedAnnual report
「We decided to and have begun implementing measures to strengthen the business, including investment in domestic yogurt production facilities, establishing a joint venture in Pakistan for the manufacture and sale of infant formula, and developing the yogurt business in the United States.」
It states that measures to strengthen the business were decided on and initiated, including the infant-formula joint venture in Pakistan, the U.S. yogurt business and domestic investment in yogurt facilities. - FY2016First statedAnnual report
「Advancing Globalization」
One of the 4 business pillars in the medium-term management plan. It also describes the establishment of an unconsolidated subsidiary in Singapore and the overseas business base provided by subsidiaries in Germany and the United States.